18:15 , Dec 8, 2016 |  BC Innovations  |  Translation in Brief

PEGylation once removed

Scientists at the Massachusetts Institute of Technology (MIT) have figured out how to use PEGylation, a covalent modification, to create a non-covalent excipient that not only extends the shelf-life of biologics but boosts their in...
21:23 , Nov 18, 2016 |  BC Week In Review  |  Company News

Arsia, Eagle deal

Eagle will acquire drug formulation and delivery company Arsia for $30 million, including $27.3 million in cash and $2.7 million in Eagle stock. Arsia is also eligible for up to $48 million in milestones. Arsia's...
23:29 , Nov 11, 2016 |  BC Extra  |  Company News

Eagle acquiring drug delivery company Arsia

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) is to acquire drug formulation and delivery company Arsia Therapeutics Inc. (Waltham, Mass.) for $30 million, including $27.3 million in cash and $2.7 million in Eagle stock. Arsia is also eligible...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Company News

Biogen, Arsia Therapeutics deal

Biogen and Arsia partnered to develop high-concentration subcutaneous formulations of IV hemophilia biologic drugs or drug candidates using Arsia’s formulation technology. Arsia has a library of more than 60 excipients that aim to reduce the...
02:33 , Dec 17, 2015 |  BC Extra  |  Company News

Arsia, Biogen in deal for subcutaneous biologics

Biogen Inc. (NASDAQ:BIIB) partnered with Arsia Therapeutics Inc. (Cambridge, Mass.) to develop subcutaneous formulations of intravenous hemophilia therapies. Arsia CEO Amy Schulman said details about the therapies covered under the deal are not disclosed, including...
08:00 , Dec 14, 2015 |  BioCentury  |  Emerging Company Profile

Subcutaneous solution

Subcutaneous delivery of biologics can eliminate or reduce visits to a hospital or doctor's office, but at the high concentrations required, an increase in interactions between the molecules causes most biologics to become too viscous...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Arsia Therapeutics management update

Arsia Therapeutics Inc. , Waltham, Mass.   Business: Cancer, Antibodies   Hired: Amy Schulman as CEO, formerly general counsel and EVP at Pfizer Inc.  ...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Venture tracks

Amy Schulman joined Polaris Partners as a venture partner. Schulman also became CEO of Polaris portfolio company Arsia Therapeutics Inc. , which is developing excipients that reduce the viscosity of biologics allowing them to be...
01:12 , Jul 30, 2014 |  BC Extra  |  Financial News

Schulman joins Polaris Partners

Amy Schulman, former general counsel and EVP at Pfizer Inc. (NYSE:PFE), joined Polaris Partners as a venture partner. Schulman also became CEO of Polaris portfolio company Arsia Therapeutics Inc. (Waltham, Mass.), which is developing excipients...